BACKGROUND: Streptococcus pneumoniae is a major cause of morbidity and mortality in developed and developing countries. No common genetic determinants of susceptibility have been defined. Mannose-binding lectin (MBL) is a key mediator of innate host immunity that activates the complement pathway and directly opsonises some infectious pathogens. Mutations in three codons in the MBL gene have been identified, and individuals homozygous for a mutant genotype have very little or no serum MBL. We did a case-control study in the UK to assess whether these mutant genotypes were associated with invasive pneumococcal disease. METHODS: The frequencies of genotypes defined by the three mutations in codons 52, 54, and 57, and a functional promoter polymorphism at -221, were compared in a two-stage study of 337 patients with invasive pneumococcal disease and 1032 controls. All individuals were recruited from an ethnically homogeneous white population in Oxfordshire, UK. Patients had S pneumoniae isolated from a normally sterile site. FINDINGS: In our initial set of participants, 28 (12%) of 229 patients and 18 (5%) of 353 controls were homozygotes for MBL codon variants (odds ratio 2.59 [95% CI 1.39-4.83], p=0.002). Neither heterozygosity for these codon variants nor the promoter polymorphism was associated with susceptibility. In a confirmatory study, 11 (10%) of 108 patients were MBL homozygotes compared with 36 (5%) of 679 controls (p=0.046). INTERPRETATION: Homozygotes for MBL codon variants, who represent about 5% of north Europeans and north Americans and larger proportions of populations in many developing countries, could be at substantially increased risk of invasive pneumococcal disease.
BACKGROUND:Streptococcus pneumoniae is a major cause of morbidity and mortality in developed and developing countries. No common genetic determinants of susceptibility have been defined. Mannose-binding lectin (MBL) is a key mediator of innate host immunity that activates the complement pathway and directly opsonises some infectious pathogens. Mutations in three codons in the MBL gene have been identified, and individuals homozygous for a mutant genotype have very little or no serum MBL. We did a case-control study in the UK to assess whether these mutant genotypes were associated with invasive pneumococcal disease. METHODS: The frequencies of genotypes defined by the three mutations in codons 52, 54, and 57, and a functional promoter polymorphism at -221, were compared in a two-stage study of 337 patients with invasive pneumococcal disease and 1032 controls. All individuals were recruited from an ethnically homogeneous white population in Oxfordshire, UK. Patients had S pneumoniae isolated from a normally sterile site. FINDINGS: In our initial set of participants, 28 (12%) of 229 patients and 18 (5%) of 353 controls were homozygotes for MBL codon variants (odds ratio 2.59 [95% CI 1.39-4.83], p=0.002). Neither heterozygosity for these codon variants nor the promoter polymorphism was associated with susceptibility. In a confirmatory study, 11 (10%) of 108 patients were MBL homozygotes compared with 36 (5%) of 679 controls (p=0.046). INTERPRETATION: Homozygotes for MBL codon variants, who represent about 5% of north Europeans and north Americans and larger proportions of populations in many developing countries, could be at substantially increased risk of invasive pneumococcal disease.
Authors: Paul Denny; Elaine Hopes; Neill Gingles; Karl W Broman; William McPheat; John Morten; Janet Alexander; Peter W Andrew; Steve D M Brown Journal: Mamm Genome Date: 2003-07 Impact factor: 2.957
Authors: Thomas R Hawn; Sarah J Dunstan; Guy E Thwaites; Cameron P Simmons; Nguyen Thuong Thuong; Nguyen Thi Ngoc Lan; Hoang Thi Quy; Tran Thi Hong Chau; Nguyen T Hieu; Stephanie Rodrigues; Marta Janer; Lue Ping Zhao; Tran Tinh Hien; Jeremy J Farrar; Alan Aderem Journal: J Infect Dis Date: 2006-09-12 Impact factor: 5.226
Authors: Ning Zhang; Quynh Ai Truong-Tran; Brian Tancowny; Kathleen E Harris; Robert P Schleimer Journal: J Immunol Date: 2007-07-01 Impact factor: 5.422
Authors: M Perez-Castellano; M Peñaranda; A Payeras; J Milà; M Riera; J Vidal; F Pujalte; A Pareja; C Villalonga; N Matamoros Journal: Clin Exp Immunol Date: 2006-08 Impact factor: 4.330
Authors: Masja Straetemans; Selma P Wiertsema; Elisabeth A M Sanders; Ger T Rijkers; Kees Graamans; Bert van der Baan; Gerhard A Zielhuis Journal: J Clin Immunol Date: 2005-01 Impact factor: 8.317